CGClaudio Melo de Gusmao

Claudio Melo de Gusmao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claudio Melo de Gusmao has a total of 179 co-authors. Here are the top co-authors by number of shared publications:

  • Laura Silveira-Moriyama

    Department of Neurology University of Campinas (UNICAMP) Campinas Brazil

    5 shared publications
  • Fernando Kok

    Division of Child Neurology, Department of Neurology Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC‐FMUSP) Sao Paulo Brazil

    4 shared publications
  • Jeff Waugh

    Division of Pediatric Neurology, University of Texas Southwestern, Dallas, TX, USA

    3 shared publications
  • Laura Silveira-Moriyama

    From the Department of Neurology (C.M.d.G., A.L.R.P.), Boston Children's Hospital, Harvard Medical School, MA; Neurology Department (C.M.d.G., L.S-M.), HC-FCM, University of Campinas, UNICAMP, Campinas, São Paulo, Brazil; Department of Neurology (I.P.d.B.), Children's Hospital of Philadelphia, PA; and Education Unit (L.S-M.), UCL Institute of Neurology, University College London, UK

    3 shared publications
  • Tamara Pringsheim

    Department of Clinical Neurosciences University of Calgary Calgary AB Canada

    3 shared publications
  • Aurélie Méneret

    Sorbonne Université INSERM, CNRS, Institut du Cerveau Paris France

    2 shared publications

Latest Publications

  • Myoclonus, Dystonia, and Ataxia in U2AF2 ‐Related Neurodevelopmental Disorder

    by Ana Luiza Viegas de Almeida, Renata Silva de Mendonça, Joemir Jábson da Conceição Brito, Vanessa Catarine Abreu Ribeiro Antunes, Leandro Tavares Lucato, Fernando Kok, Claudio Melo de Gusmao

  • Novel and Emerging Therapies for Childhood‐Onset Movement Disorders

    by Claudio M. de Gusmao, Vladimir L. Katanaev, Laura Silveira‐Moriyama, Tamara Pringsheim, Emmanuel Roze

    Childhood‐onset movement disorders comprise a heterogeneous group of rare conditions with substantial unmet therapeutic needs. Recent advances in disease gene discovery, mechanistic modeling, and translational platforms have accelerated the development of targeted therapies and enabled innovative clinical trial designs for small patient populations. To review novel and emerging therapies for childhood‐onset movement disorders, with a focus on pharmacologic strategies, disease‐modifying approaches, and patient‐centered precision therapies. We surveyed the literature, major conference proceedings, and expert networks to identify therapies approved, in clinical development, or supported by compelling preclinical data between 2022 and 2025. We focused on small molecules and genetic therapies for conditions in which movement disorders represent a prominent clinical feature. Small molecules were categorized as repurposed or novel drugs, whereas genetic therapies included gene replacement, gene editing, and RNA ‐based expression modulation. Drug repurposing approaches have shown promise in disorders related to the GNAO1 , ATP1A3 , ATM , and ADCY5 genes. Novel small molecules have advanced for Friedreich's ataxia and Tourette's syndrome. Gene replacement therapies have demonstrated clinical benefit in select neurotransmitter disorders, whereas gene editing strategies have entered preclinical development for ATP1A3 ‐related disease. Antisense oligonucleotide therapies have yielded encouraging early results across several conditions with prominent movement disorder phenotypes, including KIF1A ‐related neurological disorder, Angelman syndrome, SCN2A ‐related neurodevelopmental disorder, and ataxia‐telangiectasia. Precision‐based therapeutic strategies are rapidly reshaping the treatment landscape for childhood‐onset movement disorders. Continued progress will depend on rigorous phenotyping, careful ethical oversight, and deliberate efforts to promote equitable global access to emerging therapies. © 2026 International Parkinson and Movement Disorder Society.


  • Heterozygous RNF13 Truncating Variants Are Associated With Developmental and Epileptic Encephalopathy

    by Donald R. Latner, Susan M. Hiatt, Candice R. Finnila, Whitley V. Kelley, Marla Johnston, Jessica Patrick‐Esteve, Nour Elkhateeb, Mona A. Kamel, Tahsin Stefan Barakat, Marjon van Slegtenhorst, et al.

    Developmental and epileptic encephalopathy 73 (DEE73; OMIM 618379) is an autosomal dominant severe neurodevelopmental disorder associated with pathogenic variants in the RING finger protein 13 gene (RNF13; OMIM 609247), which encodes a transmembrane E3 ubiquitin ligase. The phenotype of affected individuals includes microcephaly, seizures, intellectual disability, developmental delay, absent or limited speech, restricted movement, cortical blindness, and skeletal defects (hip dysplasia, club feet, scoliosis). The currently known DEE73 phenotype is based on two reports of four unrelated individuals: three with missense variants in a di‐leucine motif that is essential for binding to the Adaptor Protein Complex 3 (AP‐3), and one with a truncating variant located in the last exon. This case series of an additional 13 affected individuals with RNF13 variants (2 missense, 11 truncating) supports and broadens previous reports. Importantly, it helps to define a narrow but critical region of the protein that is intolerant to truncating variation, although the gene is not highly constrained.

  • Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism

    by André Luiz Santos Pessoa, Thiago Gonçalves Guimarães, Diego de Castro dos Santos, Renata Montes Garcia Barbosa, Ellen Mourao Soares Lopes, Claudio M. de Gusmao, Pedro Lucas Grangeiro Sá Barreto Lima, Matheus Augusto Araújo Castro, Fernando Kok, Paulo Ribeiro Nobrega

    Background: Biallelic variants in DNAJC6 cause PARK‐ DNAJC6 (historically referred to as PARK19), a rare autosomal recessive juvenile‐onset dystonia‐parkinsonism syndrome. Neurodevelopmental delay or regression, epilepsy, movement disorders, and psychiatric symptoms are also present. Progression is fast with frequent bulbar, gastrointestinal involvement and early loss of ambulation. Cases: We report two siblings (17 and 14 years) harboring a novel homozygous nonsense variant in DNAJC6 , p.Cys325*, not previously described in the medical literature and absent from population databases. The variant is predicted to truncate the protein, supporting a loss‐of‐function mechanism consistent with the gene's disease biology. Both patients exhibited developmental regression, parkinsonism with dystonia, cognitive decline, dysphagia, and marked sialorrhea, with severe, accelerated functional deterioration. Levodopa produced only mild benefit; in the older sibling, dose escalation provoked an adverse reaction with sustained upgaze/ophthalmoparesis, opisthotonus, and hypertension. Literature review: We found 23 previously reported DNAJC6 patients, most with early‐onset parkinsonism with variable levodopa responsiveness, frequent developmental and psychiatric comorbidity, and prominent bulbar features. Conclusions: The novel DNAJC6 p.Cys325* variant is associated with severe, early‐onset parkinsonism and developmental regression. DNAJC6 should be considered in children and adolescents presenting with parkinsonism plus neurodevelopmental decline, particularly when levodopa benefit is modest, and dose‐related adverse motor crises occur.

  • Open Access

    Juvenile Dystonia Associated with Heterozygous Missense Variant in KCNJ10

    by Claudio M. de de Gusmao, Sara C.B. Casagrande, Matheus A. Castro, André Pessoa, Cleonisio Leite Rodrigues, Laura Silveira Moriyama, Fernando Kok, Paulo Ribeiro Nóbrega


  • Open Access

    Early Levodopa Therapy in Tyrosine Hydroxylase Deficiency

    by Claudio M. de Gusmao, Roser Pons, Ganeshwaran H. Mochida, Laura Silveira‐Moriyama, Fernando Kok


  • Open Access

    KCNMA1‐Related Episodes of Behavioral Arrest and Loss of Postural Reflexes: A Critical Reappraisal

    by Emmanuel Roze, Laura Silveira‐Moriyama, Smaranda Leu‐Semenescu, Nathalie Villeneuve, Bérénice Lecardonnel, Marie‐Céline François‐Heude, Pierre Meyer, Claudio M. de Gusmao, Agathe Roubertie

    Background: KCNMA1‐linked channelopathy is characterized by neurodevelopmental disorder, epileptic seizures and non‐epileptic paroxysmal episodes.Objectives: To describe the phenotype of paroxysmal non‐epileptic episodes related to KCNMA1 pathogenic variants.Methods: Videos of paroxysmal episodes were reviewed according to a standardized protocol by a group of movement disorders experts.Results: Fourteen videos were reviewed (6 previously published patients and a new patient). The typical pattern of an episode was (i) facial changes including dyskinetic movements of tongue and jaws (ii) behavioral arrest (iii) loss of postural reflexes that could be associated with focal body stiffness, eventually leading to fall (iv) rapid recovery without post‐ictal drowsiness. Attacks were brief, with a high daily frequency, occasionally triggered by emotion, and dramatically improved by psychostimulant therapy in three patients.Conclusions: KCNMA1‐related attacks are clearly distinguishable from paroxysmal dyskinesia, cataplexy or episodic ataxia indicating a unique phenomenological entity whose recognition will enhance accurate diagnosis and treatment.


  • Teaching Video NeuroImage: Oculomotor Abnormalities in Patients With Alternating Hemiplegia of Childhood

    by Andréia B. Azzoni, Mayara T. Sakuma, Leticia P. Sampaio, Claudio M. De Gusmao


  • Pearls & Oy‐sters: Paroxysmal Exercise-Induced Dyskinesias Due to Pyruvate Dehydrogenase Deficiency

    by Claudio M. de Gusmao, Isabella Peixoto de Barcelos, Anna L. R. Pinto, Laura Silveira-Moriyama

    Paroxysmal exercise-induced movement disorders may be caused by energy metabolism disorders, such as Glut 1 deficiency, pyruvate dehydrogenase deficiency or mitochondrial respiratory chain disorders. A 4-year-old boy with a history of febrile seizures presented with paroxysmal dystonia, triggered by exercise, or occurring at rest. Additional investigations demonstrated pallidal hyperintensities on brain MRI and low CSF glucose. Pyruvate and lactate were elevated. The clinical presentation, combined with neuroimaging abnormalities and biochemical profile (the lactate/pyruvate ratio) were clues to pyruvate dehydrogenase deficiency, a treatable metabolic disorder with neurological presentations.


  • Open Access

    Scoping Review onADCY5‐Related Movement Disorders

    by Poornima Jayadev Menon, Christelle Nilles, Laura Silveira‐Moriyama, Ruiyi Yuan, Claudio M. de Gusmao, Alexander Münchau, Miryam Carecchio, Steve Grossman, Gay Grossman, Aurélie Méneret, et al.

    Background: Adenylyl cyclase 5 (ADCY5)‐related movement disorder (ADCY5‐RMD) is a rare, childhood‐onset disease resulting from pathogenic variants in theADCY5gene. The clinical features, diagnostic options, natural history, and treatments for this disease are poorly characterized and have never been established through a structured approach.Objective: This scoping review attempts to summarize all available clinical literature on ADCY5‐RMD.Methods: Eighty‐seven articles were selected for inclusion in this scoping review. The majority of articles identified were case reports or case series.Results: These articles demonstrate that patients with ADCY5‐RMD suffer from permanent and/ or paroxysmal hyperkinetic movements. The paroxysmal episodes can be worsened by environmental triggers, in particular the sleep–wake transition phase in the early morning. Occurrence of nocturnal paroxysmal dyskinesias and perioral twitches are highly suggestive of the diagnosis when present. In the majority of patients intellectual capacity is preserved. ADCY5‐RMD is considered a non‐progressive disorder, with inter‐individual variations in evolution with aging. Somatic mosaicism, mode of inheritance and the location of the mutation within the protein can influence phenotype.Conclusions: The current evidence for therapeutic options for ADCY5‐RMD is limited: caffeine, benzodiazepines and deep brain stimulation have been consistently reported to be useful in case reports and case series.